Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chiltern Pesquisa Clinica Ltda
ClinicalTrials.gov Identifier:
NCT01032395
First received: December 14, 2009
Last updated: June 13, 2013
Last verified: June 2013
  Purpose

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of A(H1N1) inactivated influenza virus vaccine in subjects with Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus, and to compare safety and immunogenicity data with a contemporaneously enrolled control group of age-comparable, healthy subjects.

Because certain individuals may be hypo-responsive to influenza vaccination, additional studies with high-risk groups are warranted in order to determine the optimal vaccine formulation and dosing schedule for prevention of novel H1N1 virus infection.


Condition Intervention Phase
H1N1 Influenza Virus
Chronic Pulmonary Disease
Chronic Heart Disease
Diabetes Mellitus
Biological: Focetria®
Biological: Fluad®
Biological: Begrivac®
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Chiltern Pesquisa Clinica Ltda:

Primary Outcome Measures:
  • Geometric Mean HI Titer by Visit [ Time Frame: 13 months after vaccination (Day 1, Day 22, Day 43, Day 133, Day 223 and Day 403) ] [ Designated as safety issue: No ]
    Geometric mean hemagglutinin inhibition (HI) titer = GMT

  • Geometric Mean Ratio by Visit [ Time Frame: 13 months after vaccination (Day 22/Day1, Day 43/Day 1, Day 43/Day 22, Day 133/Day 43, Day 223/Day 43 and Day 403/Day 223) ] [ Designated as safety issue: No ]
    The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with chronic diseases (chronic cardiac diseases, chronic pulmonary diseases and diabetes mellitus).

  • Ratio of Immunogenicity Data by Visit (Vaccine With Adjuvant : Vaccine Without Adjuvant) [ Time Frame: 13 months after vaccination (Day 1, Day 22, Day 22/Day1, Day 43, Day 43/Day 1, Day 43/Day 22, Day 133, Day 133/Day 43, Day 223, Day 223/Day 43 and Day 403, Day 403/Day 223) ] [ Designated as safety issue: No ]
    The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with chronic diseases (chronic cardiac diseases, chronic pulmonary diseases and diabetes mellitus). Comparisons were made by vaccine group using ratios of immunogenicity data and were presented with 95% confidence intervals.

  • Percentage of Subjects Who Reached Seroprotection by Visit [ Time Frame: 13 months after vaccination (Day 22, Day 43, Day 133, Day 223 and Day 403) ] [ Designated as safety issue: No ]
    The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with chronic diseases (chronic cardiac diseases, chronic pulmonary diseases and diabetes mellitus). The percentage of subjects that reached seroprotection in comparison to the pre-vaccination result are presented by visit. Seroprotection was defined as HI titer ≥40.

  • Percent of Subjects Who Seroconverted or Had a Significant Increase in Geometric Mean Titer by Visit [ Time Frame: 13 Months after vaccination (Day 22, Day 43, Day 133, Day 223 and Day 403) ] [ Designated as safety issue: No ]
    The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with chronic diseases (chronic cardiac diseases, chronic pulmonary diseases and diabetes mellitus). The percentage of subjects that reached seroconversion or had a significant increase in comparison to the pre-vaccination result were presented by visit. Seroconversion or a significant increase was defined as HI titer ≥40 in subjects with negative results at pre-vaccination (HI titer <10) or an increase of at least 4 times in HI titer for individuals with positive results at pre-vaccination (HI titer >10) at Day 22 and Day 43 in comparison to the pre-vaccination result.

  • Difference in the Seroprotection Rates by Visit (Vaccine With Adjuvant - Vaccine Without Adjuvant) [ Time Frame: 13 Months after vaccination (Day 22, Day 43, Day 133, Day 223 and Day 403) ] [ Designated as safety issue: No ]
    The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with chronic diseases (chronic cardiac diseases, chronic pulmonary diseases and diabetes mellitus). Comparisons were made by vaccine group using differences in the percentage of subjects with seroprotection and were presented with 95% confidence intervals.

  • Differences in the Seroconversion Rates or Significant Increase by Visit (Vaccine With Adjuvant - Vaccine Without Adjuvant) [ Time Frame: 13 Months after vaccination (Day 22, Day 43, Day 133, Day 223 and Day 403) ] [ Designated as safety issue: No ]
    The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with chronic diseases (chronic cardiac diseases, chronic pulmonary diseases and diabetes mellitus). Comparisons were made by vaccine group using differences in the percentage of subjects with seroconversion/significant increase and were presented with 95% confidence intervals.


Enrollment: 342
Study Start Date: March 2010
Study Completion Date: August 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Chronic Disease Subjects Receiving Vaccine with Adjuvant
Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
Biological: Focetria®
7.5 ug of HA antigen; adjuvanted; monovalent
Biological: Fluad®
15 ug of HA antigen; adjuvanted; trivalent
Experimental: Chronic Disease Subjects Receiving Vaccine without Adjuvant
Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
Biological: Begrivac®
15 ug of antigen; non-adjuvanted; trivalent
Experimental: Healthy Subjects Receiving Vaccine with Adjuvant
Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
Biological: Focetria®
7.5 ug of HA antigen; adjuvanted; monovalent
Biological: Fluad®
15 ug of HA antigen; adjuvanted; trivalent
Experimental: Healthy Subjects Receiving Vaccine without Adjuvant
Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
Biological: Begrivac®
15 ug of antigen; non-adjuvanted; trivalent

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

For Subjects with Chronic Diseases:

  • Subjects between 18 and 70 years of age (inclusive)
  • Any sex or ethnicity
  • Outpatient or hospitalized subjects
  • Confirmed diagnosis of chronic pulmonary and/or cardiac, and/or diabetes mellitus based on the investigator's assessment (subjects may present one or more of such conditions)
  • Childbearing potential women must be willing to use an acceptable contraceptive method. Acceptable contraceptive methods are defined as one or more of the following:

    1. Hormone contraceptive (such as oral, injectable, transdermal patch, subcutaneous implant, cervical ring)
    2. Barrier (condom with spermicide or diaphragm with spermicide) at each intercourse and during the whole intercourse
    3. Intra-uterine device (IUD)
    4. Monogamous relation with vasectomized partner (must have been vasectomized at least six months before the volunteer entered the study)
  • Subjects capable of following all the study procedures and available for all visits scheduled to the investigation site
  • Subjects capable of understanding the nature and risk of the study proposed and sign the consent form
  • The study subjects may have other underlying chronic diseases that do not involve immunosuppression (e.g. osteoarticular diseases, stable, non-progressive, non-severe neurologic disorders without cognitive impairment, ophthalmologic diseases, hypothyroidism, etc.), but their symptoms/signs must be under control through medical follow-ups and drug therapy

For Healthy Subjects:

  • Subjects between 18 and 70 years of age (inclusive)
  • Any sex and ethnicity
  • Subjects with good health as determined by medical history, physical evaluation, and investigator's clinical opinion
  • Childbearing potential women must be willing to use an acceptable contraceptive method. Acceptable contraceptive methods are defined as one or more of the following:

    1. Hormone contraceptive (such as oral, injectable, transdermal patch, subcutaneous implant, cervical ring)
    2. Barrier (condom with spermicide or diaphragm with spermicide) at each intercourse and during the whole sexual intercourse
    3. Intra-uterine device (IUD)
    4. Monogamous relation with vasectomized partner (must have been vasectomized for at least six months before the volunteer entered the study)
  • Subjects capable of respecting all the study procedures and available for all the visits scheduled at the investigation site
  • Subjects capable of understanding the nature and risk of the study proposed and sign the consent form

Exclusion Criteria:

For Subjects with Chronic Diseases

  • Previous laboratory confirmed diagnosis of an infection by the novel H1N1 virus
  • Administration of other vaccine against the novel H1N1 virus within 3 months prior to inclusion in the study
  • Any recent vaccine given within the last 21 days (inclusive)
  • History of allergic reaction to an influenza vaccine in the past, or a current or previous occurrence of allergy to egg or egg protein, kanamycin, and neomycin sulfate
  • Acute febrile disease (vaccination may be delayed up to 3 days after the resolution of the symptoms)
  • History of cancer, except for skin cancer, including Kaposi's Sarcoma, basal cell carcinoma, and non-invasive malignancy related to HPV
  • History of chronic hepatic or renal disease
  • History of cognitive disorders
  • History of progressive or severe neurological disorders, including Guillain-Barré Syndrome
  • Pregnancy or breast-feeding
  • Use of immunomodulatory therapy, including cyclosporin,interleukins, and interferons, within 3 months prior to inclusion in the study
  • Receipt of parenteral immunoglobulin, hemotherapy, and/or plasma derivatives within 3 months prior to inclusion in the study
  • Life expectancy of at least 12 months
  • Receipt of any investigational product within 12 months prior to inclusion in the study

For Healthy Subjects:

  • Previous laboratory confirmed diagnosis of an infection by the new virus H1N1
  • Receipt of another vaccine against the new virus H1N1 within 3 months prior to inclusion in the study
  • Any recent vaccine given within the last 21 days (inclusive)
  • History of allergic reaction to influenza vaccine in the past, or a current or previous allergy to egg or egg protein, kanamycin, and neomycin sulfate
  • Acute febrile disease (the vaccination may be delayed up to 3 days after symptoms resolution)
  • Pregnancy or breast-feeding
  • Receipt of parenteral immunoglobulin, hemotherapy, and/or plasma derivatives within 3 months prior to inclusion in the study
  • Receipt of any investigational product within 12 months prior to inclusion in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01032395

Locations
Brazil
Centro de Estudos de Pneumologia da Faculdade de Medicina do ABC
Santo André, SP, Brazil
Instituto de Ensino e Pesquisa em Geriatria e Gerontologia
São Paulo, SP, Brazil
Sponsors and Collaborators
Chiltern Pesquisa Clinica Ltda
  More Information

Publications:
Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated influenza vaccines. In. Plotkin SA, Orenstein WA, Offit PA. Vaccines 5th ed. WB Saunders. Phila PA 2008; 291-309
Dominguez-Cherit G, Lapinsky SE, Macias AE et al. Critically ill patients with 2009 influenza (H1N1) infection in Mexico. JAMA 2009;302(17):1880-1887

Responsible Party: Chiltern Pesquisa Clinica Ltda
ClinicalTrials.gov Identifier: NCT01032395     History of Changes
Other Study ID Numbers: V111_16TP
Study First Received: December 14, 2009
Last Updated: June 13, 2013
Health Authority: Brazil: National Health Surveillance Agency

Keywords provided by Chiltern Pesquisa Clinica Ltda:
H1N1
Pulmonary Disease
Heart Disease
Diabetes
Influenza
immunogenicity
safety
tolerability

Additional relevant MeSH terms:
Chronic Disease
Diabetes Mellitus
Heart Diseases
Influenza, Human
Lung Diseases
Disease Attributes
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 25, 2014